Targeting cancer cells: magnetic nanoparticles as drug carriers
暂无分享,去创建一个
Christoph Alexiou | Ernst Huenges | Christian Bergemann | Fritz G. Parak | C. Alexiou | M. Kremer | C. Bergemann | T. Nawroth | E. Huenges | F. Parak | W. Arnold | R. Jurgons | R. Schmid | Roland Jurgons | Wolfgang Arnold | Gerhard Wanner | Thomas Nawroth | Roswitha J. Schmid | Marcus Kremer | Gerhard Wanner
[1] R Langer,et al. Drug delivery. Drugs on target. , 2001, Science.
[2] R Weissleder,et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. , 1989, AJR. American journal of roentgenology.
[3] Christoph Alexiou,et al. Magnetic drug targeting--biodistribution of the magnetic carrier and the chemotherapeutic agent mitoxantrone after locoregional cancer treatment. , 2003, Journal of drug targeting.
[4] C. Alexiou,et al. Locoregional cancer treatment with magnetic drug targeting. , 2000, Cancer research.
[5] P Reichardt,et al. Clinical experiences with magnetic drug targeting: a phase I study with 4'-epidoxorubicin in 14 patients with advanced solid tumors. , 1996, Cancer research.
[6] Robert Langer,et al. Drugs on Target , 2001, Science.
[7] D. Huhn,et al. Preclinical experiences with magnetic drug targeting: tolerance and efficacy. , 1996, Cancer research.